by Elec23 | Apr 11, 2025 | News&events
We are proud to announce that VisMederi has once again been included in the Financial Times FT 1000 ranking, placing 483rd among Europe’s fastest-growing companies in 2025. The eighth annual list, compiled in collaboration with Statista, recognises companies that have...
by Elec23 | Apr 9, 2025 | News&events
VisMederi’s R&D Department, in collaboration with the University of Siena, University of Palermo, and University of Bari, has developed and validated a new high-throughput neutralization assay for human Metapneumovirus (hMPV) A and B. This pivotal work aims to...
by Elec23 | Apr 7, 2025 | News&events
Emanuele Montomoli (CSO & Founder) and Alessandro Manenti (CDO) are co-authors of a new scientific publication on a Phase II/III clinical study evaluating the immunogenicity, safety, and tolerability of a new SARS-CoV-2 booster vaccine. The study represents an...
